Skip to main content

Advertisement

SpringerLink
Log in

A review of new approaches in Her-2 targeting and 1H MRI application

  • Review Article
  • Published:
Medicinal Chemistry Research Aims and scope Submit manuscript

Abstract

To date, the Her-2 receptor is the most frequently detected breast cancer biomarker which can be monitored on the surface of tumors by proton magnetic resonance imaging (1H MRI). In the past decade, we observed major advances in the development of 1H MRI as a diagnostic tool in cancer studies. 1H MRI is noninvasive method and can be used to explore tumor biology, cancer cell surface morphology and provide information about drug efficacy, absorption, distribution, and elimination. This review describes current studies of Her-2 targeting with trastuzumab and the application of 1H MRI to Her-2 receptor detection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adolphi NL, Butler KS, Lovato DM, Tessier TE, Trujillo JE, Hathaway HJ, Fegan DL, Monson TC, Stevens TE, Huber DL, Ramu J, Milne ML, Altobelli SA, Bryant HC, Larson RS, Flynn ER (2012) Imaging of Her-2 targeted magnetic nanoparticles for breast cancer detection: comparison of SQUID-detected magnetic relaxometry and MRI. Contrast Media Mol Imaging 7(3):308–319

    Article  CAS  PubMed  Google Scholar 

  • Altai M, Varasteh Z, Andersson K, Eek A, Boerman O, Orlova A (2013) In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of Her-2 expression in tumors. Cancer Biother Radiopharm 28(3):187–189

  • Artemov D, Mori N, Okollie B, Bhujwalla ZM (2003) MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 49:403–408

    Article  CAS  PubMed  Google Scholar 

  • Bartusik D, Tomanek B (2012) Detection of trastuzumab efficacy using 1H MRI ex vivo of breast cancer cells. Med Chem Res 21(9):2316–2319

    Article  CAS  Google Scholar 

  • Baselga J (2001) Clinical trials of herceptin. Eur J Cancer 37:S18–S24

    Article  CAS  PubMed  Google Scholar 

  • Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L (1996) Phase II study of weekly intravenous recombinant humanized anti-p185 Her-2 monoclonal antibody in patients with Her-2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737–744

    CAS  PubMed  Google Scholar 

  • Bottomley PA, Foster TH, Argersinger RE, Pfeifer LM (1984) A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1–100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age. Med Phys 11:425–448

    Article  CAS  PubMed  Google Scholar 

  • Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP (2001) Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19:2722–2730

    CAS  PubMed  Google Scholar 

  • Chatell M, Darcel F, Certaines F, Benoist L, Bernard AM (1986) T 1 and T 2 proton nuclear magnetic resonance relaxation times in vitro and human intracranial tumours. J Neuro Oncol 3:315–321

    Article  Google Scholar 

  • Chaturvedi R, Asim M, Piazuelo MB, Yan F, Barry DP, Sierra JC, Delgado AG, Hill S, Casero RA Jr, Bravo LE, Dominguez RL, Correa P, Polk DB, Washington MK, Rose KL, Schey KL, Morgan DR, Peek RM Jr, Wilson (2014) KT activation of EGFR and ERBB2 by helicobacter pylori results in survival of gastric epithelial cells with DNA damage. Gastroenterology S0016–5085(14):00192–09005

    Google Scholar 

  • Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-Her-2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648

    CAS  PubMed  Google Scholar 

  • Cohen V, Agulnik JS, Ang C, Kasymjanova G, Batist G, Small D, Brandao G, Chong G, Miller WH Jr (2010) Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors. Cancer 116(18):4309–4317

    Article  CAS  PubMed  Google Scholar 

  • Davies DE, Chamberlin SG (1996) Targeting the epidermal growth factor receptor for therapy of carcinomas. Bioch Biophys Res Commun 51:1101–1110

    CAS  Google Scholar 

  • Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN (2002) Phase II study of weekly docetaxel and trastuzumab for patients with Her-2 overexpressing metastatic breast cancer. J Clin Oncol 20:1800–1808

    Article  CAS  PubMed  Google Scholar 

  • Funovics MA, Kapeller B, Hoeller C, Su HS, Kunstfeld R, Puig S, Macfelda K (2004) MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Mag Reson Imag 22(6):843–850

    Article  CAS  Google Scholar 

  • Goldenberg MM (1999) Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21:309–318

    Article  CAS  PubMed  Google Scholar 

  • Goldstein R, Sosabowski J, Vigor K, Chester K, Meyer T (2013) Developments in single photon emission computed tomography and PET-based Her-2 molecular imaging for breast cancer. Expert Rev Anticancer Ther 13(3):359–373

    Article  CAS  PubMed  Google Scholar 

  • Harris AL, Nicholson S, Sainsbury R, Wright C, Farndon J (1992) Epidermal growth factor receptor and other oncogenes as prognostic markers. J Nat Can Inst 11:181–187

    Google Scholar 

  • Kimijima I, Yoshida K, Tamura R, Moriya T (2013) Effectiveness of multi-detector row computed tomography in detection of the presence and extent of ductal carcinoma in situ. Breast Cancer 20(1):23–26

    Google Scholar 

  • Klinke DJ 2nd, Kulkarni YM, Wu Y, Byrne-Hoffman C (2014) Inferring alterations in cell-to-cell communication in Her-2(+) breast cancer using secretome profiling of three cell models. Biotechnol Bioeng 111(9):1853–1863

    Article  CAS  PubMed  Google Scholar 

  • Le XF, Pruefer F, Bast R (2005) Her-2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 4(1):87–95

    Article  CAS  PubMed  Google Scholar 

  • Moretti E, Desmedt C, Biagioni C, Regan MM, Oakman C, Larsimont D, Galardi F, Piccart-Gebhart M, Sotiriou C, Rimm DL, Di Leo A (2013) TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. Future Oncol 9(10):1477–1487

    Article  CAS  PubMed  Google Scholar 

  • O’Shaughnessy JA, Vukelja S, Marsland T, Kimmel G, Ratnam S, Pippen JE (2004) Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 5(2):142–147

    Article  PubMed  Google Scholar 

  • Pegram MD, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancer. Oncogene 18:2241–2251

    Article  CAS  PubMed  Google Scholar 

  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Herceptin adjuvant (HERA) trial study team, trastuzumab after adjuvant chemotherapy in Her-2-positive breast cancer. N Engl J Med 353(16):1659–1672

    Article  CAS  PubMed  Google Scholar 

  • Pisanu ME, Ricci A, Paris L, Surrentino E, Liliac L, Bagnoli M, Canevari S, Mezzanzanica D, Podo F, Iorio E, Canese R (2014) Monitoring response to cytostatic cisplatin in a Her2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy. Br J Cancer 110(3):623–625

    Article  Google Scholar 

  • Poptani H, Puumalainen AM, Gro¨hn OH, Loimas S, Kainulainen R, Yla-Herttuala S, Kauppinen RA (1998) Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Cancer Gene Ther 5:101–109

    CAS  PubMed  Google Scholar 

  • Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, Ward R, Soliz R, Osborne CK, Schiff R (2011) Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the Her pathway in Her-2/neu-overexpressing breast tumor xenografts. Clin Cancer Res 17:1351–1361

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Rodrigues LM, Stubbs M, Robinson SP, Newell B, Mansi J, Griffiths JR (2005) The C-neu mammary carcinoma in oncomice; characterization and monitoring response to treatment with herceptin by magnetic resonance methods. MAGMA 17(3–6):260–270

    Google Scholar 

  • Ross RJ, Thompson JS, Kim K, Bailey RA (1982) Nuclear magnetic resonance imaging and evaluation of human breast tissue: preliminary clinical trials. Radiology 143:195–205

    Article  CAS  PubMed  Google Scholar 

  • Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D’Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hud CA (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587–2595

    CAS  PubMed  Google Scholar 

  • Shen S, Xu Y, Sun Q, Wang C, Zhou Y, Mao F, Guan J, Lin Y, Wang X, Han S (2014) Trastuzumab administered concurrently with anthracycline-containing adjuvant regimen for breast cancer. Zhonghua Zhong Liu Za Zhi 36(2):132–136

    CAS  PubMed  Google Scholar 

  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 235:177–182

    Article  CAS  PubMed  Google Scholar 

  • Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against Her-2 for metastatic breast cancer that overexpresses Her-2. N Engl J Med 344:783–792

    Article  CAS  PubMed  Google Scholar 

  • Stack JP, Redmond OM, Codd MB, Dervan PA, Ennis JT (1990) Breast disease: tissue characterization with Gd-DTPA enhancement profiles. Radiology 174(2):491–494

    Article  CAS  PubMed  Google Scholar 

  • Vogel CL, Cobleigh M, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ (2001) First-line, single-agent herceptin (trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer 37:25–29

    Article  PubMed  Google Scholar 

  • Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, Skala MC (2013) Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer. Cancer Res 73(20):6164–6174

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Wojcinski S, Stefanidou N, Hillemanns P, Degenhardt F (2013) The biology of malignant breast tumors has an impact on the presentation in ultrasound: an analysis of 315 cases. BMC Womens Health 13:47

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biology and Chemistry, Southern Polytechnic State University, 1100 South Marietta Parkway, Marietta, GA, 30060, USA

    Dorota Bartusik

  2. Department of Medical Physics, Cross Cancer Institute, 11560 University Ave, Edmonton, AB, T6G 1Z2, Canada

    Dorota Bartusik & Boguslaw Tomanek

  3. Natural Sciences Department, Shorter University, 315 Shorter Ave, Rome, GA, 30165, USA

    David Aebisher

  4. Department of Clinical Neurosciences and Radiology, University of Calgary, 3330 Hospital Drive NW, Calgary, AB, T2N 4N1, Canada

    Boguslaw Tomanek

  5. Institute of Nuclear Physics, Polish Academy of Sciences, Radzikowskiego 152, 31-342, Kraków, Poland

    Boguslaw Tomanek

Authors
  1. Dorota Bartusik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Aebisher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Boguslaw Tomanek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dorota Bartusik.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bartusik, D., Aebisher, D. & Tomanek, B. A review of new approaches in Her-2 targeting and 1H MRI application. Med Chem Res 24, 1365–1368 (2015). https://doi.org/10.1007/s00044-014-1237-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00044-014-1237-0

Keywords

Search

Navigation